Glucose metabolism via the pentose phosphate pathway (PPP) is typically upregulated in tumors, including gliomas. We previously showed that hyperpolarized δ-[1-13C]gluconolactone metabolism via the PPP to 6-phospho-[1-13C]gluconate (6PG) differentiates tumor from contralateral normal brain in preclinical glioma models. Here, we examined the ability of hyperpolarized δ-[1-13C]gluconolactone to probe response to temozolomide, which is a key chemotherapeutic drug for glioma patients. Our studies in live cells and rats bearing orthotopic gliomas indicate that 6PG production from hyperpolarized δ-[1-13C]gluconolactone serves as an early biomarker of response to temozolomide, a finding that has the potential to improve treatment response monitoring for glioma patients.
This abstract and the presentation materials are available to members only; a login is required.